Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Inks COVAX Pact with Optional Arrangement, Commits 17.2 Billion Yen Upfront
September 16, 2020
- New Vice Health Minister Aiming to Get Coronavirus Drugs and Vaccines to Japanese People “as Quickly as Possible”
September 16, 2020
- MHLW Panel Allows Osaka Univ. Hospital to Continue JANP Study, Requires Report by Year End: Data Scandal
September 15, 2020
- Prioritized Flu Vaccinations for Elderly from October 1, Others Asked to Wait until October 26
September 14, 2020
- Japan to Officially Sign Up for COVAX Pact; Govt to Hammer Out Payment on Sept. 15
September 14, 2020
- Komeito Prods Govt to Tap State Coffers for Coronavirus Vaccinations
September 11, 2020
- MHLW Calls for Smooth Supply of Flu Shots as It Anticipates Surging Demand
September 11, 2020
- Japan to Steadily Collect Info on AstraZeneca Trial Pause: Minister
September 11, 2020
- Japan to Require Pledges from Troubled Generic Makers to Skip Next Listing Round If Supply Issues Occur Again
September 10, 2020
- Label Revisions Ordered for Plaquenil, Relumina
September 10, 2020
- Japan Scrambles to Collect Info on AstraZeneca Vaccine Trial Pause, Sticks to 2021 H1 Immunization Goal
September 10, 2020
- MHLW Erases Hydroxychloroquine, 4 Other Drugs from COVID-19 Treatment Guide
September 10, 2020
- Bid-Rigging Scandal by Wholesalers “Interferes with” Development of Pharma Industry: MHLW Bureau Chief
September 9, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- 1st COVID-19 Case Confirmed at NIHS
September 9, 2020
- Coronavirus Vaccines “Will Need to Be Evaluated More Carefully than Ordinary Medicines”: Top MD Bureaucrat
September 8, 2020
- Sakigake Status Should Not Be Granted to Novartis Products until It Takes Prevention Measures for Approval Delay: Pharma Bureau Chief
September 8, 2020
- Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Clears MHLW Panel
September 8, 2020
- Medical Professionals to Be Prioritized in COVID-19 Vaccination: Govt Panel
September 8, 2020
- PMDA Reviewing Safety Risks for Takecab, 2 Other Drugs
September 7, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…